Ann: APAS PharmaQC Commercially Ready - Performance Finalised, page-81

Hi Benny,

Brent did a proactiv investors interview last week following the 18th annual bioshares summit. Video attached below

I can see your point on 4 and- and is was part of key takeaways I have taken from this video

1/ 3 x faster than manual review on petrie dish analysis and just as effective
2/ Astra Zeneca was referred to as a "cornerstone customer"
3/18 months ago strategy was pivoted from infectious diseases to pharma manufacturing which is a $2.8bn addressable market
4/ The "big one" coming is Astra Zeneca finalizing validating the tech then they will look at rolling out to their biggest manufacturing sites globally -looking at sept/oct mark
5/ New bit of information we have shared they have started an evaluation with two more top 10 global pharma companies